Modality
ADC
MOA
AuroraAi
Target
EZH2
Pathway
JAK/STAT
NB
Development Pipeline
Preclinical
~May 2014
→ ~Aug 2015
Phase 1
~Nov 2015
→ ~Feb 2017
Phase 2
May 2017
→ Dec 2028
Phase 2Current
NCT04401988
2,009 pts·NB
2022-09→2027-05·Not yet recruiting
NCT07393032
1,622 pts·NB
2017-05→2028-12·Recruiting
3,631 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-05-231.1y awayPh2 Data· NB
2028-12-042.7y awayPh2 Data· NB
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2
Recruit…
P2
Not yet…
Catalysts
Ph2 Data
2027-05-23 · 1.1y away
NB
Ph2 Data
2028-12-04 · 2.7y away
NB
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04401988 | Phase 2 | NB | Not yet recr... | 2009 | EASI-75 |
| NCT07393032 | Phase 2 | NB | Recruiting | 1622 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |